Clinical Trials

Phase 2 testing of HIV vaccine developed with Vaccine Research Center initiated

Published in Vaccine Weekly, November 16th, 2005

GenVec, Inc. (GNVC) announced that the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), U.S. National Institutes of Health, has begun phase 2 clinical testing of an experimental adenovector-based HIV vaccine candidate developed in collaboration between GenVec and the VRC.

The double-blind, placebo-controlled phase 2 study will enroll a total of 480 healthy volunteers who will be randomized 1:1 to receive either vaccine or placebo. The treatment group will receive a DNA plasmid injection (the "prime") followed by the adenovector-based booster vaccine. Both vaccines contain DNA segments from the three major HIV subtypes,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2005-11-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry